DB:GBMB

Stock Analysis Report

Executive Summary

Inovio Pharmaceuticals, Inc., a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases.


Snowflake Analysis

Limited growth with imperfect balance sheet.

Share Price & News

How has Inovio Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: GBMB's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-8.3%

GBMB

0.4%

DE Biotechs

-0.9%

DE Market


1 Year Return

6.0%

GBMB

10.0%

DE Biotechs

12.8%

DE Market

Return vs Industry: GBMB underperformed the German Biotechs industry which returned 10% over the past year.

Return vs Market: GBMB underperformed the German Market which returned 12.8% over the past year.


Shareholder returns

GBMBIndustryMarket
7 Day-8.3%0.4%-0.9%
30 Day-9.7%-3.2%-0.4%
90 Day58.0%4.6%2.3%
1 Year6.0%6.0%10.3%10.0%16.3%12.8%
3 Year-43.7%-43.7%49.4%47.8%15.8%5.7%
5 Year-44.6%-44.6%13.9%11.5%19.7%3.3%

Price Volatility Vs. Market

How volatile is Inovio Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Inovio Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

11.01x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate GBMB's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate GBMB's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: GBMB is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: GBMB is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate GBMB's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: GBMB is overvalued based on its PB Ratio (11x) compared to the DE Biotechs industry average (3.5x).


Next Steps

Future Growth

How is Inovio Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

35.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: GBMB is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: GBMB is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: GBMB is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: GBMB's revenue (58% per year) is forecast to grow faster than the German market (5.2% per year).

High Growth Revenue: GBMB's revenue (58% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if GBMB's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Inovio Pharmaceuticals performed over the past 5 years?

-26.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: GBMB is currently unprofitable.

Growing Profit Margin: GBMB is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: GBMB is unprofitable, and losses have increased over the past 5 years at a rate of -26.9% per year.

Accelerating Growth: Unable to compare GBMB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GBMB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: GBMB has a negative Return on Equity (-319.41%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Inovio Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: GBMB's short term assets ($98.8M) exceed its short term liabilities ($19.5M).

Long Term Liabilities: GBMB's short term assets ($98.8M) exceed its long term liabilities ($95.9M).


Debt to Equity History and Analysis

Debt Level: GBMB's debt to equity ratio (194%) is considered high.

Reducing Debt: Insufficient data to determine if GBMB's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: GBMB has a low level of unsold assets or inventory.

Debt Coverage by Assets: GBMB's debt is covered by short term assets (assets are 1.4x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: GBMB has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: GBMB has less than a year of cash runway if free cash flow continues to reduce at historical rates of -29.5% each year


Next Steps

Dividend

What is Inovio Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.3%markettop25%3.6%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate GBMB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate GBMB's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if GBMB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GBMB's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of GBMB's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.7yrs

Average management tenure


CEO

J. Kim (50yo)

10.7yrs

Tenure

US$3,081,043

Compensation

Dr. J. Joseph Kim, Ph.D has been the Chief Executive Officer of Inovio Pharmaceuticals, Inc. (alternate name: Inovio Biomedical Corp) since June 1, 2009 and has been its President since October 6, 2009. Dr ...


CEO Compensation Analysis

Compensation vs Market: J.'s total compensation ($USD3.08M) is above average for companies of similar size in the German market ($USD802.74K).

Compensation vs Earnings: J.'s compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
J. Kim
CEO, President & Director10.7yrsUS$3.08m2% $7.0m
Peter Kies
Chief Financial Officer17.7yrsUS$1.33m0.11% $391.7k
Jacqueline Shea
COO & Executive VP0.9yrsno datano data
Laurent Humeau
Chief Scientific Officer & Executive VP1.3yrsno data0.050% $173.5k
Ben Matone
Director of Investor Relations2.2yrsno datano data
Jeffrey Richardson
Vice President of Communications & Strategic Relations0.4yrsno datano data
E. Brandreth
Senior Vice President of Quality Assurance0yrsno datano data
Jessica Lee
Senior Vice President of Clinical Operations & Global Integration0yrsno datano data
Ami Brown
Senior Vice President of Regulatory Affairs0yrsno datano data
Stephen Kemmerrer
Senior Vice President of Engineering Development0yrsno datano data

1.7yrs

Average Tenure

52.5yo

Average Age

Experienced Management: GBMB's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
J. Kim
CEO, President & Director10.7yrsUS$3.08m2% $7.0m
Wendy Yarno
Independent Director2.2yrsUS$138.80k0.016% $56.4k
Lota Zoth
Independent Director1.1yrsno data0.0040% $14.1k
Simon Benito
Chairman of Board of Directors1.1yrsUS$151.30k0.043% $150.4k
David Weiner
Chairman of the Scientific Advisory Board & Director20.1yrsUS$447.64k0.79% $2.7m
Stanley Plotkin
Member of Scientific Advisory Board10.7yrsno datano data
Angel Venegas
Independent Director7.7yrsUS$136.55k0.067% $233.0k
Ann Miller
Independent Director0.9yrsno datano data
Anthony Ford-Hutchinson
Member of Scientific Advisory Board7.9yrsno datano data
Rafi Ahmed
Member of Scientific Advisory Board1.3yrsno datano data

4.9yrs

Average Tenure

62.5yo

Average Age

Experienced Board: GBMB's board of directors are considered experienced (4.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: GBMB insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 7.2%.


Top Shareholders

Company Information

Inovio Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Inovio Pharmaceuticals, Inc.
  • Ticker: GBMB
  • Exchange: DB
  • Founded: 1979
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$379.597m
  • Listing Market Cap: US$349.457m
  • Shares outstanding: 101.36m
  • Website: https://www.inovio.com

Number of Employees


Location

  • Inovio Pharmaceuticals, Inc.
  • 660 West Germantown Pike
  • Suite 110
  • Plymouth Meeting
  • Pennsylvania
  • 19462
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
INONasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDMay 1992
GBMBDB (Deutsche Boerse AG)YesCommon StockDEEURMay 1992

Biography

Inovio Pharmaceuticals, Inc., a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system’s tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. The company is involved in conducting and planning clinical studies of its proprietary SynCon immunotherapies for human papillomavirus-caused pre-cancers and cancers; glioblastoma multiforme; hepatitis B virus; hepatitis C virus; human immunodeficiency virus; Ebola virus; middle east respiratory syndrome; and Zika virus. Its partners and collaborators include The Wistar Institute; University of Pennsylvania; GeneOne Life Science Inc.; ApolloBio Corporation; Regeneron Pharmaceuticals, Inc.; Genentech, Inc.; Plumbline Life Sciences, Inc.; Drexel University; National Institute of Allergy and Infectious Diseases; United States Military HIV Research Program; U.S. Army Medical Research Institute of Infectious Diseases; National Institutes of Health; HIV Vaccines Trial Network; Defense Advanced Research Projects Agency; the Parker Institute for Cancer Immunotherapy; QIAGEN N.V.; Coalition for Epidemic Preparedness Innovations; and Beijing Advaccine Biotechnology Co. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/23 22:34
End of Day Share Price2020/02/21 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.